🔍

SMS Pharmaceuticals Limited (SMSPHARMA)

₹450.50 +6.01% last close, 16 Oct

📊 NSE: SMSPHARMA 🏢 Pharmaceuticals - Indian - Bulk Drugs 📢 Latest filing: 30 Sep 2026 📝 Analysis written: 14 Dec 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, SMS Pharmaceuticals' revenue was ₹207 Cr (+5.6% year on year, -13.0% on the previous quarter), and net profit ₹20.2 Cr (-1.4% year on year); the operating margin was 19.8%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹207	+5.6%	-13.0%
Operating profit	₹41.0	+4.0%	+2.4%
Net profit	₹20.2	-1.4%	-38.8%
EPS (₹)	2.23	-3.5%	-36.1%
Operating margin	19.8%	—	—

Full quarterly financials → Results calendar →

SMSPHARMA delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 25.48% of the SMSPHARMA shares traded on NSE were taken to delivery, against the stock's own 20-session average of 38.22%. The price rose 6.01% on unusually low delivery, so more of the move than usual was intraday trading.

25.48%Delivery, 16 Oct

38.22%Own 20-session average

0.6×Volume vs its average

₹450.50NSE close · +6.01%

Delivery in the last 5 sessions: 43.7% · 42.2% · 51.3% · 43.2% · 25.5%

Delivery across the market →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

SMS Pharmaceuticals AGM: Shareholders Approve All 7 Resolutions, Including Loans & RPTs

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 30 Sep 2026, 12:45 PM

SMS Pharmaceuticals Limited concluded its 38th Annual General Meeting on September 29, 2026, with all 7 resolutions passed by the requisite majority. Key approvals included the FY26 dividend, material related-party transactions with VKT Pharma Private Limited, and authorization to extend loans to subsidiary SMS Peptides Private Limited. For the material related-party transactions, public institutional and non-institutional shareholders voted 99.30% in favour (promoter votes of 63,745,010 shares abstained/invalidated).

All 7 resolutions passed with requisite majority at the 38th AGM held on September 29, 2026
Approval granted for Material Related Party Transactions with VKT Pharma Private Limited with 99.30% votes in favour from public voters
Special resolution passed to provide loan to subsidiary company SMS Peptides Private Limited with 99.30% votes in favour
Re-appointment of Mr. Ramesh Babu Potluri as Chairman & Managing Director approved with 99.43% votes in favour

💡 Track the quarterly disclosures for the quantum and terms of loans disbursed to SMS Peptides Private Limited and transaction values with VKT Pharma.

SMS Pharmaceuticals to Attend Emkay Global Investor Meet on Sep 15, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 10 Sep 2026, 03:13 PM

SMS Pharmaceuticals Limited has scheduled an analyst and institutional investor interaction for September 15, 2026, in Hyderabad. The company's management will participate in a group meeting organized under the Emkay Global Investors Meeting. Management confirmed that discussions will be restricted to publicly available industry and company information, with no unpublished price sensitive information (UPSI) to be shared.

Meeting scheduled for September 15, 2026
Venue set for Hyderabad as a group meeting
Interaction arranged with Emkay Global Investors Meeting
No unpublished price sensitive information (UPSI) will be discussed

💡 Monitor post-meet investor presentations or disclosure filings if uploaded to the exchanges following the September 15 interaction.

SMS Pharma Dispatches FY26 Annual Report; Sets Sep 22 Record Date for ₹0.40 Dividend

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Sep 2026, 03:45 PM

SMS Pharmaceuticals Limited has issued an intimation regarding the dispatch of its FY2025-26 Integrated Annual Report and Notice of the 38th AGM to shareholders. The AGM is scheduled to take place virtually on September 29, 2026. The company confirmed a proposed final dividend of ₹0.40 per equity share of face value ₹1 each, with the record date fixed as September 22, 2026. Eligible dividend payments will be processed within 30 days of declaration at the AGM.

38th Annual General Meeting scheduled for September 29, 2026, at 10:30 AM IST via VC/OAVM.
Proposed dividend of Rs. 0.40 per equity share of face value Rs 1/-.
Record date / cut-off date for dividend eligibility set as September 22, 2026.
Dividend to be paid within 30 days from the date of declaration at the AGM.

💡 Shareholders seeking dividend eligibility should ensure demat and KYC details are updated before September 22, 2026, and track AGM proceedings on September 29, 2026.

SMS Pharmaceuticals Submits FY26 Business Responsibility and Sustainability Report

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 04 Sep 2026, 12:04 PM

SMS Pharmaceuticals Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26 as part of its Annual Report under SEBI LODR Regulation 34(2)(f). The filing reports FY26 standalone turnover of Rs 886.87 Cr and a net worth of Rs 804.79 Cr, with API manufacturing accounting for 99.21% of turnover. Exports contributed 66% of total turnover across 45 international markets. The company reported zero product recalls and zero data breaches during the fiscal year.

API manufacturing accounted for 99.21% of total revenue in FY26
Exports contributed 66% of turnover across 45 international markets
Company reported FY26 turnover of Rs 886.87 Cr and net worth of Rs 804.79 Cr
Total permanent workforce stood at 1,266 employees and 351 permanent workers
Zero product recalls (voluntary or forced) and zero customer complaints on data privacy or safety

💡 Track upcoming quarterly financial results and progress on the company's Rs 280 Cr backward integration capex.

SMS Pharma Dispatches FY26 Annual Report; Sets 38th AGM & Dividend Record Date for Sept 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Sep 2026, 11:52 AM

SMS Pharmaceuticals Limited has issued notice for its 38th Annual General Meeting (AGM) scheduled for September 29, 2026, via video conferencing. The company set September 22, 2026, as the record date for dividend eligibility and cut-off for e-voting. Remote e-voting will commence on September 25, 2026, and conclude on September 28, 2026. In the accompanying FY26 Annual Report, the company highlighted full-year revenue of ₹887 crore (up 13% YoY) and PAT of ₹102 crore (up 47% YoY).

38th Annual General Meeting to be held on September 29, 2026, at 10:30 AM IST
Record Date for Dividend and AGM e-voting eligibility set for September 22, 2026
Remote e-voting window open from September 25, 2026 (9:00 AM IST) to September 28, 2026 (5:00 PM IST)
Book closure scheduled from September 23, 2026 to September 29, 2026 (both days inclusive)
FY26 highlights include revenue of ₹887 crore, EBITDA of ₹171 crore (20% margin), and PAT of ₹102 crore

💡 Shareholders eligible for dividend payout and voting should note the record date of September 22, 2026, and cast their votes during the e-voting period.

CARE Reaffirms SMS Pharma at 'CARE A/A1'; Revises Long-Term Outlook to 'Stable' from 'Positive'

🟡 NEUTRAL ⭐ 5/10

OTHER 📅 02 Sep 2026, 08:55 AM

CARE Ratings has reaffirmed SMS Pharmaceuticals' long-term bank facilities rating at 'CARE A' and short-term facilities at 'CARE A1'. The outlook on long-term facilities has been revised from 'Positive' to 'Stable', while the rated long-term amount was enhanced to ₹570.07 crore from ₹350.87 crore. Total bank facilities rated stand at ₹622.90 crore, including ₹349.07 crore in term loans primarily to support capex programs.

Long-term bank facilities rating reaffirmed at 'CARE A', with outlook revised from 'Positive' to 'Stable'
Long-term rated facility size increased to ₹570.07 crore from ₹350.87 crore
Short-term bank facilities rating reaffirmed at 'CARE A1' for ₹52.83 crore
Total rated bank facilities increased to ₹622.90 crore (covering ₹349.07 crore term loans and ₹221.00 crore fund-based limits)

💡 Track the commissioning and cash flow generation from the ₹280 crore backward integration project to see if debt levels normalize and return ratios expand.

SMS Pharma Revises FY26 Dividend Record Date to Sept 22 and AGM to Sept 29, 2026

🟡 NEUTRAL ⭐ 2/10

DIVIDEND 📅 27 Aug 2026, 11:38 AM

SMS Pharmaceuticals Limited has announced a revised schedule for its 38th Annual General Meeting (AGM) and dividend eligibility. The record date for determining shareholders eligible for the FY26 dividend has been postponed from September 16, 2026, to September 22, 2026. Consequently, the 38th AGM will now take place via video conferencing on September 29, 2026, instead of September 23, 2026. The company's share transfer books and register of members will remain closed from September 23 to September 29, 2026.

Record date for FY26 dividend eligibility revised to September 22, 2026 (from September 16, 2026)
38th AGM rescheduled to September 29, 2026 (originally planned for September 23, 2026)
Book closure period set from September 23, 2026, to September 29, 2026 (both days inclusive)
Board approved the changes via circular resolution citing administrative and scheduling constraints

💡 Investors seeking dividend eligibility must ensure shares are held in their demat account as of the revised record date of September 22, 2026, subject to shareholder approval at the AGM.

SMS Pharmaceuticals Reschedules 38th AGM to Sep 29, 2026; Dividend Record Date Now Sep 22

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Aug 2026, 11:29 AM

SMS Pharmaceuticals Limited has announced a revised schedule for its 38th Annual General Meeting (AGM) and associated dividend record date. Due to administrative and scheduling constraints, the 38th AGM for FY26 will now be conducted on September 29, 2026, instead of September 23, 2026. Consequently, the record date for determining shareholder eligibility for the FY26 dividend has been pushed to September 22, 2026, from September 16, 2026. The share transfer books and register of members will remain closed from September 23 to September 29, 2026.

38th Annual General Meeting rescheduled to Tuesday, September 29, 2026 (previously September 23, 2026)
Dividend record date for FY26 revised to Tuesday, September 22, 2026 (previously September 16, 2026)
Book closure period set from September 23, 2026, to September 29, 2026 (both days inclusive)
AGM to be conducted virtually via Video Conferencing (VC) / Other Audio-Visual Means (OAVM)

💡 Investors seeking dividend eligibility must hold shares before the revised record date of September 22, 2026, and track AGM proceedings on September 29, 2026.

₹0.40 Dividend: SMS Pharmaceuticals Sets Record Date and TDS Guidelines for FY 2025-26

🟡 NEUTRAL ⭐ 4/10

DIVIDEND 📅 06 Aug 2026, 12:55 PM

SMS Pharmaceuticals has announced the procedural details for its final dividend of ₹0.40 per share for FY 2025-26. The company has fixed September 16, 2026, as the record date to determine shareholder eligibility. A standard TDS of 10% will apply to resident individuals with a valid PAN, while a higher rate of 20% applies to those without. Shareholders must submit tax-related documents by September 9, 2026, to claim exemptions or lower withholding rates.

Final dividend of ₹0.40 per equity share (40% of face value ₹1) recommended for FY 2025-26.
Record date for determining dividend entitlement is fixed as September 16, 2026.
TDS of 10% for resident individuals with PAN; no TDS if total annual dividend is ≤ ₹10,000.
Deadline for submission of tax exemption forms (Form 121/DTAA documents) is September 9, 2026.
Annual General Meeting (AGM) to approve the dividend is scheduled for September 23, 2026.

💡 Shareholders should ensure their PAN is linked to Aadhaar and bank account details are updated with their Depository Participant before the September 16 record date.

SMSPHARMA Q1 Revenue at ₹207 Cr; ₹280 Cr Capex and ₹50 Cr Peptide Infusion Underway

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 01 Aug 2026, 05:10 PM

SMS Pharmaceuticals reported a steady Q1FY27 with revenue growing 6% YoY to ₹207 crore and PAT increasing 8% to ₹20 crore. The company is aggressively pursuing a ₹280 crore capex program (representing ~32% of TTM revenue) to be completed by FY27, focusing on capacity expansion and new products. A strategic infusion of ₹50 crore as a loan into SMS Peptides Private Limited highlights a shift toward high-margin R&D. High-value products now contribute 51% of total revenue, helping sustain EBITDA margins at 20%.

Q1FY27 Revenue grew 6% YoY to ₹207 crore, while PAT rose 8% to ₹20 crore.
Ongoing ₹280 crore capex program is on track for FY27 completion, targeting a net asset turnover of 1.75x.
Board approved a ₹50 crore loan infusion into subsidiary SMS Peptides to establish a dedicated R&D facility.
High-value product share increased to 51% in Q1FY27, up from 47% in FY26.
Completed 4 DMF/CEP filings in Q1, tracking toward a full-year target of 10 filings.

💡 Investors should monitor the progress of the ₹280 crore capex completion and the commercialization timeline of the peptide R&D facility, which are critical for achieving the 1.75x asset turnover target.

SMSPHARMA Q1 FY27: 6% Revenue Growth to ₹207 Cr; ₹160 Cr Remaining Capex on Track

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 01 Aug 2026, 05:06 PM

SMS Pharmaceuticals reported a steady Q1 FY27 with revenue growing 6% YoY to ₹207.0 Cr and PAT increasing 8% to ₹20.20 Cr. Gross margins expanded by 217 bps to 36% due to backward integration, though EBITDA margins remained flat at 20% due to higher freight and employee costs. The company is progressing on its ₹280 Cr capex plan, with ₹160 Cr (approx. 18% of TTM revenue) remaining to be spent by FY27. Additionally, the board approved a ₹50 Cr loan to its peptide subsidiary to bolster its R&D capabilities.

Revenue increased 6% YoY to ₹207.0 Cr, supported by a 69% growth in the Anti-Retro Viral (ARV) segment.
Gross margin improved to 36% from 34% YoY, reflecting structural benefits from backward integration.
Remaining capex of ₹160 Cr is scheduled for completion by FY27 to support new niche molecule launches.
Board approved a ₹50 Cr loan to subsidiary SMS Peptides Private Limited for its dedicated R&D facility.
Anti-diabetic segment revenue saw a significant 69% YoY decline, dropping to ₹20.08 Cr from ₹65.16 Cr.

💡 Investors should monitor the commercialization timeline of the 6-8 niche molecules expected by the end of FY27 and the impact of the ₹50 Cr peptide investment on future CDMO revenue. Watch for margin recovery if geopolitical freight pressures ease as management anticipates.

SMSPHARMA Q1 Revenue Grows 5.6% to ₹207 Cr; ₹50 Cr Loan to Subsidiary Approved

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 31 Jul 2026, 06:05 PM

SMS Pharmaceuticals reported a steady Q1 FY27 with consolidated revenue rising 5.6% YoY to ₹206.96 Cr. Consolidated Profit Before Tax (PBT) increased by 11.6% YoY to ₹27.20 Cr, showing improved operational efficiency. The Board approved a ₹50 Cr unsecured loan to its 99.99% subsidiary, SMS Peptides, which represents approximately 6.2% of the company's net worth. Additionally, the Chairman and Managing Director was re-appointed for a five-year term, ensuring leadership continuity through 2031.

Consolidated Revenue from Operations reached ₹206.96 Cr, up from ₹196.05 Cr in the same quarter last year.
Consolidated Profit Before Tax (PBT) grew to ₹27.20 Cr, an 11.6% increase over the ₹24.37 Cr reported in Q1 FY26.
Approved an unsecured loan of up to ₹50 Cr to subsidiary SMS Peptides Private Limited for business purposes.
Re-appointed Mr. Ramesh Babu Potluri as Chairman and Managing Director for a 5-year term effective October 1, 2026.
Fixed September 16, 2026, as the record date for the final dividend for the financial year 2025-26.

💡 Investors should monitor the performance of the new peptide subsidiary and the progress of the ₹280 Cr backward integration project intended to boost margins.

SMSPHARMA Q1 Profit Up 16% to ₹21.13 Cr; ₹50 Cr Loan to Subsidiary Approved

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 31 Jul 2026, 05:39 PM

SMS Pharmaceuticals reported a steady Q1 FY27 with consolidated net profit rising 16% YoY to ₹21.13 Cr. Revenue from operations grew 5.6% YoY to ₹206.96 Cr, though it saw a sequential decline from Q4 FY26. The board approved a significant unsecured loan of up to ₹50 Cr to its 99.99% subsidiary, SMS Peptides, representing approximately 6.2% of the company's net worth. Additionally, the company fixed September 16, 2026, as the record date for the FY26 dividend and re-appointed its CMD for a five-year term.

Consolidated Net Profit increased 16% YoY to ₹21.13 Cr for the quarter ended June 30, 2026.
Revenue from operations stood at ₹206.96 Cr, up from ₹196.05 Cr in the same quarter last year.
Approved an unsecured loan of up to ₹50 Cr to subsidiary SMS Peptides Private Limited for business purposes.
Fixed September 16, 2026, as the Record Date for determining dividend eligibility for FY 2025-26.
Re-appointed Mr. Ramesh Babu Potluri as Chairman and Managing Director for a 5-year term until September 2031.

💡 Investors should monitor the performance of the new subsidiary, SMS Peptides, and the utilization of the ₹50 Cr loan, alongside the progress of the ongoing ₹280 Cr backward integration project.

Rs 21.13 Cr Q1 PAT: SMSPHARMA Reports 16% YoY Profit Growth; MD Re-appointed for 5 Years

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 31 Jul 2026, 05:33 PM

SMS Pharmaceuticals reported a steady Q1 FY27 with standalone PAT rising 16% YoY to Rs 21.13 Cr, despite a modest 5.6% growth in revenue to Rs 206.96 Cr. The Board approved the re-appointment of promoter Ramesh Babu Potluri as Chairman and MD for a five-year term starting October 2026, ensuring leadership continuity. Additionally, the company authorized a loan of up to Rs 50 Cr to its 99.99% subsidiary, SMS Peptides, representing approximately 6.2% of the company's net worth. A record date of September 16, 2026, has been set for the FY26 dividend payment.

Standalone Net Profit grew 16% YoY to Rs 21.13 Cr in Q1 FY27 compared to Rs 18.21 Cr in Q1 FY26
Revenue from operations increased 5.6% YoY to Rs 206.96 Cr from Rs 196.05 Cr
Approved an unsecured loan of up to Rs 50 Cr to subsidiary SMS Peptides Private Limited for business purposes
Re-appointed Mr. Ramesh Babu Potluri as MD for a 5-year term effective October 1, 2026, to September 30, 2031
Fixed September 16, 2026, as the Record Date for determining dividend eligibility for FY 2025-26

💡 Investors should monitor the progress of the Rs 280 Cr backward integration project mentioned in company strategy and the operational ramp-up of the new peptide subsidiary.

SMSPHARMA Q1 Net Profit Up 16% YoY to ₹21.1 Cr; ₹50 Cr Loan to Subsidiary Approved

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 31 Jul 2026, 05:26 PM

SMS Pharmaceuticals reported a steady Q1 FY27 with standalone net profit rising 16% YoY to ₹21.13 crore, despite a 13% sequential revenue decline to ₹206.96 crore. The board approved a ₹50 crore unsecured loan to its 99.99% subsidiary, SMS Peptides, representing approximately 6.2% of the company's net worth. Additionally, CMD Ramesh Babu Potluri was re-appointed for a five-year term, and September 16, 2026, was fixed as the record date for the FY26 dividend.

Standalone Net Profit grew 16% YoY to ₹21.13 crore for the quarter ended June 30, 2026
Consolidated Revenue from Operations stood at ₹206.96 crore, a 5.5% increase over Q1 FY26
Approved an unsecured loan of up to ₹50 crore to subsidiary SMS Peptides Private Limited for business purposes
Re-appointed Ramesh Babu Potluri as Chairman and Managing Director for a 5-year term starting October 1, 2026
Fixed September 16, 2026, as the record date for determining dividend eligibility for FY26

💡 Monitor the utilization of the ₹50 crore loan by the new subsidiary (SMS Peptides) and the execution of the ₹280 crore backward integration project to see if it drives the targeted margin expansion.

View All SMSPHARMA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The Anti-Retroviral (ARV) segment saw a significant recovery, increasing its revenue contribution to 20% in FY24 from just 3% in FY23. Ibuprofen revenue grew 1.6x in FY24. Overall revenue for Q2 FY26 reached INR 242 Cr, a 23% YoY increase from INR 197 Cr in Q2 FY25. FY25 total revenue stood at INR 788 Cr, up 11% from INR 712 Cr in FY24.

Geographic Revenue Split

As of Q2 FY26, the revenue split is: EOU/SEZ/DE Sales (27%), Europe (26%), North America (24%), India (15%), and Asia excluding India (9%). Regulatory markets collectively account for 88% of total revenue.

Profitability Margins

Net Profit Margin improved to 8.74% in FY25 from 6.97% in FY24, a 25% increase. Gross margins expanded by 30% YoY in Q2 FY26, primarily driven by successful backward integration initiatives. Return on Net Worth increased by 19% to reach 11.00% in FY25.

EBITDA Margin

EBITDA margin stood at 20% in Q2 FY26, representing a 54% YoY increase. The operating profit margin for FY25 was 18.68%, up 9% from 17.10% in FY24. The company targets a sustained 20% EBITDA margin for FY26 through operating leverage and backward integration.

Capital Expenditure

The company is executing a INR 280 Cr capex program scheduled for completion by November 2026. This follows a previous INR 250 Cr capex aimed at driving new product launches and expanding the CMO business.

Credit Rating & Borrowing

Long-term bank facilities (INR 350.87 Cr) are rated CARE A; Positive (upgraded from Stable). Short-term facilities (INR 52.83 Cr) were upgraded to CARE A1 from CARE A2+. Interest coverage ratio improved 47% to 7.89x in FY25 due to higher EBITDA.

⚙️ Operational Drivers

Raw Materials

Key raw materials include intermediates for Ibuprofen and ARV drugs. While specific chemical names are not listed, backward integration for these materials is a core strategy to reduce the 30% margin volatility previously experienced.

Import Sources

The company is actively reducing dependence on imports through backward integration, particularly to mitigate risks from international supply chains in Asia and Europe.

Capacity Expansion

Current total reactor volume is 3,120 KL. The company operates one of Asia’s largest production blocks for Ibuprofen at its Vishakhapatnam facility. Planned expansion via the INR 280 Cr capex aims to support 8-10 new product launches in the next 12-18 months.

Raw Material Costs

Raw material costs are being optimized through backward integration, which contributed to a 30% YoY expansion in gross margins in Q2 FY26. Historically, input price escalation in FY23 led to negative margins in the Ibuprofen segment before stabilizing.

Manufacturing Efficiency

The company targets a net asset turnover of 1.5x, which it identifies as among the best in the industry. Efficiency is driven by advanced plant engineering and a large technical team of 100+ scientists.

Logistics & Distribution

Export sales, including deemed exports, constituted approximately 67% of gross sales revenue in FY23, requiring extensive global distribution networks to serve 800+ customers.

📈 Strategic Growth

Expected Growth Rate

20%

Growth Strategy

Growth will be achieved through a three-pronged strategy: completing the INR 280 Cr backward integration project to boost margins, launching 8-10 new products in therapeutic areas like anti-diabetic and anti-migraine, and expanding the CMO business. The company also leverages its JV with Spanish giant Chemo Iberica S.A. to penetrate regulated markets.

Products & Services

Active Pharmaceutical Ingredients (APIs) and intermediates for therapeutic segments including Anti-Retroviral (ARV), Anti-Diabetic, Anti-Inflammatory (Ibuprofen), Anti-Migraine (Triptans), and Anti-Ulcerants.

Brand Portfolio

SMS Pharmaceuticals Limited (Corporate Brand).

New Products/Services

Planned launch of 8-10 new products in the next 12-18 months. Since FY22, 20 new products have already been added to the portfolio.

Market Expansion

Focusing on strengthening presence in regulated markets (US and Europe) which currently contribute to the majority of export revenue. The company currently exports to over 75 countries.

Market Share & Ranking

The company claims #1 global and domestic leadership in key products, including being the world's largest manufacturer of Ranitidine API historically and a leader in anti-migraine triptans.

Strategic Alliances

Maintains a strategic Joint Venture (JV) with Spanish pharmaceutical company Chemo Iberica S.A. for product development and market access.

🌍 External Factors

Industry Trends

The Indian API industry is shifting toward backward integration to reduce China-dependency and moving toward niche, high-value molecules. SMS is positioned as a vertically integrated player with a focus on R&D and globally compliant facilities.

Competitive Landscape

Operates in a highly competitive and fragmented API market. Key competitors include large and mid-sized Indian and global API manufacturers in the ARV and Ibuprofen segments.

Competitive Moat

Moat is built on high switching costs for regulated market customers, 120+ DMF filings, and USFDA/PMDA approved facilities (Unit II and VII). These are sustainable due to the complex, lengthy, and expensive nature of the regulatory approval process for new competitors.

Macro Economic Sensitivity

Sensitive to global pharmaceutical demand and Indian government 'pro-policies' for API exports, which are projected to grow at an 8.3% CAGR to $22 billion by 2030.

Consumer Behavior

Increasing global prevalence of chronic diseases like diabetes and migraine is fueling long-term demand for the company's specific API portfolio.

Geopolitical Risks

Trade barriers and regulatory changes in the US and Europe (regulated markets) pose risks to the 88% of revenue sourced from these regions.

⚖️ Regulatory & Governance

Industry Regulations

Strict adherence to USFDA, PMDA Japan, EDQM (Europe), and ANVISA (Brazil) standards is mandatory for operations. Non-compliance risks include regulatory bans on products or facilities.

Environmental Compliance

The company provides comprehensive safety training and manages environment hazards; it complies with corporate governance as per SEBI (LODR) regulations.

⚠️ Risk Analysis

Key Uncertainties

Regulatory risk is the primary uncertainty; any adverse finding by the USFDA could impact 88% of revenue. Raw material price volatility and the successful timely completion of the INR 280 Cr capex are also critical.